122 related articles for article (PubMed ID: 2609289)
1. Identification and characterisation of an antithrombin III mutant (AT Dublin 2) with marginally decreased heparin reactivity.
Daly M; Ball R; O'Meara A; Hallinan FM
Thromb Res; 1989 Nov; 56(4):503-13. PubMed ID: 2609289
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of a new antithrombin III familial variant (AT Dublin) with possible increased frequency in children with cancer.
Daly M; O'Meara A; Hallinan FM
Br J Haematol; 1987 Apr; 65(4):457-62. PubMed ID: 3472589
[TBL] [Abstract][Full Text] [Related]
3. Analysis of antithrombin III microheterogeneity by isoelectric focusing in polyacrylamide gels and immunoblotting.
Daly M; Hallinan F
Thromb Res; 1985 Oct; 40(2):207-14. PubMed ID: 4071470
[TBL] [Abstract][Full Text] [Related]
4. Characterization of antithrombin III from human plasma by two-dimensional gel electrophoresis and capillary electrophoretic methods.
Kremser L; Brückner A; Heger A; Grunert T; Buchacher A; Josic D; Allmaier G; Rizzi A
Electrophoresis; 2003 Dec; 24(24):4282-90. PubMed ID: 14679575
[TBL] [Abstract][Full Text] [Related]
5. Interaction of S-protein of complement with thrombin and antithrombin III during coagulation. Protection of thrombin by S-protein from antithrombin III inactivation.
Podack ER; Dahlbäck B; Griffin JH
J Biol Chem; 1986 Jun; 261(16):7387-92. PubMed ID: 3754869
[TBL] [Abstract][Full Text] [Related]
6. Ability of high-affinity heparin fractions with decreasing affinity for antithrombin III to activate ATIII isoforms.
Carlson TH; Kolman MR; Frees A; Babcock T
Thromb Res; 1990 Aug; 59(3):521-30. PubMed ID: 2237824
[TBL] [Abstract][Full Text] [Related]
7. AT III Barcelona: a familial quantitative-qualitative AT III deficiency.
Grau E; Fontcuberta J; Félez J; de Diego I; Soto R; Rutllant ML
Thromb Haemost; 1988 Feb; 59(1):13-7. PubMed ID: 3363529
[TBL] [Abstract][Full Text] [Related]
8. Quantitative and qualitative congenital deficiency of antithrombin III: a new molecular variant called ATIII-Barcelona 2.
Fontcuberta J; Grau E; Rubio N; Félez J; Rutllant ML
Thromb Res; 1988 Jul; 51(1):75-81. PubMed ID: 3413737
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of antithrombin III, activated protein C and heparin on the inhibition of the tissue thromboplastin-mediated coagulation.
Hirahara K; Etoh Y; Matsuishi T; Suzuki N; Kurata M
Chem Pharm Bull (Tokyo); 1989 Mar; 37(3):692-6. PubMed ID: 2752479
[TBL] [Abstract][Full Text] [Related]
10. The effect of sulfation on the anticoagulant and antithrombin III-binding properties of a heparin fraction with low affinity for antithrombin III.
Schoen P; Wielders S; Petitou M; Lindhout T
Thromb Res; 1990 Feb; 57(3):415-23. PubMed ID: 2315894
[TBL] [Abstract][Full Text] [Related]
11. Antithrombin "Chicago": a functionally abnormal molecule with increased heparin affinity causing familial thrombophilia.
Bauer KA; Ashenhurst JB; Chediak J; Rosenberg RD
Blood; 1983 Dec; 62(6):1242-50. PubMed ID: 6640109
[TBL] [Abstract][Full Text] [Related]
12. Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children.
Mitchell L; Piovella F; Ofosu F; Andrew M
Blood; 1991 Nov; 78(9):2299-304. PubMed ID: 1718494
[TBL] [Abstract][Full Text] [Related]
13. [Antithrombin III. Physiologic, physiopathologic and laboratory aspects].
de Sousa JC; Ferreira R; Carriço F; Nunes V; Geraldes MJ; Parreira F; Ribeiro C
Rev Port Cardiol; 1991 Sep; 10(9):693-9. PubMed ID: 1747261
[TBL] [Abstract][Full Text] [Related]
14. Formation of activated protein C and inactivation of cell-bound thrombin by antithrombin III at the surface of cultured vascular endothelial cells--a comparative study of two anticoagulant mechanisms.
Delvos U; Meusel P; Preissner KT; Müller-Berghaus G
Thromb Haemost; 1987 Feb; 57(1):87-91. PubMed ID: 3590084
[TBL] [Abstract][Full Text] [Related]
15. Induced hyperglycemia alters antithrombin III activity but not its plasma concentration in healthy normal subjects.
Ceriello A; Giugliano D; Quatraro A; Consoli G; Stante A; Dello Russo P; D'Onofrio F
Diabetes; 1987 Mar; 36(3):320-3. PubMed ID: 3803739
[TBL] [Abstract][Full Text] [Related]
16. [Studies on antithrombin III. I. Purification and some properties of antithrombin III (ATIII), and the relationship between plasma antithrombin activity and ATIII antigen concentration (author's transl)].
Takahashi K
Nihon Ketsueki Gakkai Zasshi; 1980 Oct; 43(5):879-88. PubMed ID: 7234301
[No Abstract] [Full Text] [Related]
17. Abnormalities in thrombin-antithrombin pathway in AL amyloidosis.
Gamba G; Montani N; Anesi E; Palladini G; Lorenzutti F; Perfetti V; Merlini G
Amyloid; 1999 Dec; 6(4):273-7. PubMed ID: 10611948
[TBL] [Abstract][Full Text] [Related]
18. Purification and properties of guinea pig antithrombin III.
Heck L; Rosenberg R; Remold H
Prep Biochem; 1979; 9(4):359-77. PubMed ID: 504072
[TBL] [Abstract][Full Text] [Related]
19. Important role of arginine 129 in heparin-binding site of antithrombin III. Identification of a novel mutation arginine 129 to glutamine.
Gandrille S; Aiach M; Lane DA; Vidaud D; Molho-Sabatier P; Caso R; de Moerloose P; Fiessinger JN; Clauser E
J Biol Chem; 1990 Nov; 265(31):18997-9001. PubMed ID: 2229057
[TBL] [Abstract][Full Text] [Related]
20. Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the beta-antithrombin III isoform with enhanced heparin affinity.
Picard V; Ersdal-Badju E; Bock SC
Biochemistry; 1995 Jul; 34(26):8433-40. PubMed ID: 7599134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
